Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Inclusion Criteria

• •A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria
• •Currently one of the following groups:
• •1. Group A: Anti-TNF Therapy Group
• •* Maintenance monotherapy: infliximab (at least every 8 weeks), golimumab (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly)
• •* Combination Therapy: Anti-TNF Combination Therapy Group on anti-TNF therapy as described above along with either methotrexate, azathioprine, or 6MP
• •2. Group B: Non-TNG biologic
• •* Ustekinumab Therapy: on either ustekinumab monotherapy or combination therapy with methotrexate, azathioprine, or 6MP
• •* Vedolizumab Therapy: on either vedolizumab monotherapy or combination therapy with methotrexate, azathioprine, or 6MP
• •* Risankizumab Therapy: 360mg at least every 8 weeks
• •3. Group C: Janus Kinase Therapy
• •* Tofacitinib Therapy: at least 5mg PO BID
• •* Upadactinib Therapy: at least 15mg PO daily
• •Patient has been on stable treatment for IBD for at least three months
• •Must be able to provide research samples between 28-65 days post influenza or Covid-19 vaccination.